OX40L
Sanofi’s Amlitelimab Clears Regulatory Bar, Raises New Investor Doubts
SNY performance by TradingView Sanofi (NASDAQ: SNY, Euronext Paris: SAN)’s amlitelimab still looks like a viable U.S. approval candidate, but it is no longer the clear successor to Dupixent that investors once hoped for. The latest data keeps the program alive from a regulatory standpoint, yet introduces enough uncertainty that the stock is unlikely to…
